Insiders, Pharma

After a slate of small, tack-on acquisitions, is Merck ready to pull the trigger on a big M&A deal?

Ken Frazier onstage at a dealmakers event in New York City,November 2018 The New York Times

Like any good big pharma CEO, Merck’s Ken Frazier likes to paint a big, positive picture when he talks with analysts about R&D. But in his latest quarterly sit-down with the Wall Street crowd, Cowen's Steve Scala offered an unusual pushback on Frazier’s assertion that Merck — a storied outfit with a long list of blockbusters to its credit — has one of the broadest pipelines it’s seen in more than 20 years.

“What are we missing externally that Merck sees internally?” asked Scala.

Frazier came back with their 3 top cancer programs for Keytruda, Lynparza (partnered with AstraZeneca) and Lenvima. He went on to cite “a formidable internal pipeline of assets in oncology over 20 unique mechanisms” and highlighted vaccines and an antibiotic extension program.

The exchange underscores some growing tension on Wall Street that Merck has too many eggs in one very large — and increasingly competitive — basket. After building up its oncology arm around its star $7 billion-and-growing oncology franchise for Keytruda — recently augmented by their big deal with AstraZeneca on Lynparza — the mighty Merck doesn’t have a whole lot of late-stage R&D work to boast about. And it definitely has the numbers to go biggish if it wants to, particularly as GlaxoSmithKline, Eli Lilly, Bristol-Myers and Roche and others in the big pharma class start picking up assets in blockbuster acquisition packages.

Here’s the multibillion-dollar question:

Should Merck be thinking big about a major M&A deal around the late-stage pipeline? Maybe something in the $10 billion bolt-on range? Maybe one that isn’t ultimately all about Keytruda and immuno-oncology?

On March 7, just a few days from now, R&D chief Roger Perlmutter will celebrate the 6th anniversary of his appointment. So we decided to take a look at all the buyouts and collaborations the company has done during his tenure, and before, to get a close look at what the BD team there has been doing. Chris Dokomajilar at DealForma has pulled every M&A deal, commercial and R&D pact over the past decade, and it offers a clear road map on where the money has been going.

You can see it all in precise detail in the charts below.

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->